<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Hepatitis A virus infection: Treatment and prevention</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Hepatitis A virus infection: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Hepatitis A virus infection: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjiv Chopra, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Lai, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth B Rand, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis A virus (HAV) infection is prevalent in many resource-limited countries and is among the most common preventable infections acquired by travelers  (<a class="graphic graphic_figure graphicRef69392" href="/d/graphic/69392.html" rel="external">figure 1</a>). Tools for prevention of HAV infection include vaccination, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, and attention to hygienic practices.</p><p>Humans are the only known reservoir for HAV; therefore, the virus could be eradicated with successful employment of widespread prevention strategies. Since <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> became available in the United States in 1995, the rate of HAV infection has declined by 95 percent  (<a class="graphic graphic_figure graphicRef60763" href="/d/graphic/60763.html" rel="external">figure 2</a>).</p><p>Issues related to prevention of HAV are reviewed here. The epidemiology, clinical manifestations, diagnosis, and management of HAV infection are discussed separately. (See  <a class="medical medical_review" href="/d/html/2692.html" rel="external">"Hepatitis A virus infection in adults: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H1235658502"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>HAV infection is usually self-limited, and treatment consists of supportive care. Medications that might cause liver damage or are metabolized by the liver should be used with caution. Full clinical and biochemical recovery is observed within three months in 85 percent of patients, and complete recovery is observed by six months in nearly all patients [<a href="#rid1">1</a>].</p><p>Patients with fulminant hepatic failure require aggressive supportive therapy and should be transferred to a center capable of performing liver transplantation. (See  <a class="medical medical_review" href="/d/html/3570.html" rel="external">"Acute liver failure in adults: Management and prognosis"</a>.)</p><p class="headingAnchor" id="H2216772138"><span class="h1">PROTECTION PRIOR TO EXPOSURE</span><span class="headingEndMark"> — </span>Tools for prevention of HAV infection include vaccination, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>, and attention to hygienic practices. Indications for pre-exposure protection and clinical approach are discussed in the following sections.</p><p class="headingAnchor" id="H490225068"><span class="h2">Indications</span><span class="headingEndMark"> — </span>We are in agreement with recommendations issued by the Advisory Committee on Immunization Practices (ACIP) of the United States Centers for Disease Control and Prevention, which recommends protection (ideally vaccination) prior to potential hepatitis A exposure for the following individuals  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) [<a href="#rid2">2-9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All children aged 12 to 23 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All children and adolescents aged 2 to 18 years who have not previously received <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> (ie, children and adolescents are recommended for catch-up vaccination). </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For infants age 6 to 11 months who are traveling internationally, vaccination should be administered; the travel-related dose should not be counted toward the routine two-dose series [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals at increased risk for HAV infection</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals traveling to or working in countries with high or intermediate rates of HAV; some experts advise that travelers outside the United States consider hepatitis A vaccination regardless of their destination [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Men who have sex with men.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who use injection or noninjection illegal drugs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with occupational risk for exposure, including individuals working with HAV-infected primates or with HAV in a research laboratory.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who anticipate close personal contact with an international adoptee.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals experiencing homelessness.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unvaccinated individuals in outbreak settings who are at risk for HAV infection or at risk for severe disease from HAV.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals in settings that provide services to adults in which a high proportion of individuals are at increased risk for HAV infection (eg, settings with a focus on those who use injection or noninjection illegal drugs, group homes, and nonresidential day care facilities for developmentally disabled persons).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Individuals at increased risk for severe disease from HAV infection:</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals with chronic liver disease, including but not limited to individuals with hepatitis B virus infection, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, or an alanine aminotransferase or aspartate aminotransferase level persistently greater than twice the upper limit of normal.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals ≥1 year with HIV infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other individuals recommended for vaccination</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pregnant women at risk for HAV infection or severe disease from HAV infection based on risk categories summarized above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any person who requests vaccination.</p><p></p><p>The World Health Organization (WHO) has stated that whether or not to include the vaccine in routine childhood immunizations depends on the local context [<a href="#rid11">11</a>]. The proportion of susceptible people in the population and the level of exposure to the virus should be considered. Generally speaking, countries with intermediate endemicity will benefit the most from universal immunization of children. Countries with low endemicity may consider vaccinating high-risk adults. In countries with high endemicity, the use of vaccine is limited as most adults are naturally immune.</p><p>Individuals who do not need routine vaccination against hepatitis A include:</p><p class="bulletIndent1"><span class="glyph">●</span>Children under 12 months of age</p><p class="bulletIndent1"><span class="glyph">●</span>Childcare center personnel (in the absence of an outbreak)</p><p class="bulletIndent1"><span class="glyph">●</span>Health care workers (in the absence of an outbreak)</p><p class="bulletIndent1"><span class="glyph">●</span>Food service workers (in the absence of an outbreak)</p><p class="bulletIndent1"><span class="glyph">●</span>Individuals who receive blood products for clotting disorders (eg, hemophilia) </p><p class="bulletIndent1"><span class="glyph">●</span>Sewage workers</p><p class="bulletIndent1"><span class="glyph">●</span>Residents of institutions for developmentally disabled individuals</p><p></p><p>Food service workers have a critical role in common-source foodborne outbreaks, but they are not at increased risk for hepatitis A because of their occupation. Consideration may be given to HAV vaccination of food service workers in areas where community-wide outbreaks are occurring and regional health authorities or private employers determine that vaccination is cost-effective [<a href="#rid12">12</a>]. (See <a class="local">'Protection following exposure'</a> below.)</p><p>Routine HAV vaccination is not necessary for childcare center personnel or health care workers; vaccination of these individuals may be warranted in an outbreak setting. (See <a class="local">'Protection following exposure'</a> below.)</p><p>HAV vaccination of individuals who receive blood products for clotting disorders (eg, hemophilia) was previously recommended but is no longer recommended by the ACIP as of 2020 [<a href="#rid2">2</a>]. In the past, blood product sterilization procedures consisted of treatment with solvents and detergents, which inactivated lipid-enveloped viruses but not nonenveloped viruses such as HAV; additional sterilization procedures are now common. In addition, most individuals with clotting disorders in the United States receive sterilized recombinant clotting factor concentrates, eliminating risk for HAV contamination. </p><p class="headingAnchor" id="H586198546"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>The primary tool for protection against hepatitis A prior to exposure is vaccination, which is superior to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> with respect to achievable antibody concentrations and durability of immune response [<a href="#rid13">13,14</a>]. For individuals at risk for hepatitis A exposure who are allergic to the <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> or are &lt;12 months of age, passive immunization via immune globulin may be given.</p><p class="headingAnchor" id="H2232957255"><span class="h3">Role of prevaccine serology</span><span class="headingEndMark"> — </span>There is no indication for serologic testing of children prior to vaccination. The decision to pursue prevaccination serologic testing of adults should be based on the expected prevalence of immunity, whether testing will interfere with initiation of vaccination, and the cost of vaccination compared with the cost of testing [<a href="#rid15">15,16</a>].</p><p>Individuals for whom prevaccination serologic testing is most cost effective include adults from areas with high or intermediate HAV endemicity  (<a class="graphic graphic_figure graphicRef60763" href="/d/graphic/60763.html" rel="external">figure 2</a>), older adolescents, adults in certain population groups (ie, Native Americans including Alaska natives, and Hispanic individuals), and adults in groups with high prevalence of infection (such as injection drug users). Prevaccination serologic testing of adults &gt;40 may be cost effective [<a href="#rid16">16</a>]; according to a large population-based survey conducted from 1988 to 1994, more than one-third of adults &gt;40 in the United States had anti-HAV antibodies [<a href="#rid17">17</a>].</p><p>Serologic testing following vaccination is not required in immunocompetent hosts given the high rate of vaccine response among adults and children [<a href="#rid15">15</a>]. In general, completion of the vaccination may be presumed to confer lifelong protection.</p><p class="headingAnchor" id="H3671502428"><span class="h3">Vaccination</span></p><p class="headingAnchor" id="H9097689"><span class="h4">Available vaccines</span><span class="headingEndMark"> — </span>Two single-antigen inactivated <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccines</a> are licensed in the United States: HAVRIX and VAQTA [<a href="#rid18">18,19</a>]. A combination inactivated vaccine, TWINRIX, is also licensed in the United States; it contains both hepatitis A (HAVRIX) and hepatitis B (Engerix-B).</p><p><a class="drug drug_general" data-topicid="16818" href="/d/drug information/16818.html" rel="external">Combined hepatitis A virus and typhoid vaccine</a> formulations (Viatim and Vivaxim) are available in some areas outside the United States.</p><p>Live attenuated hepatitis A vaccine is not available in the United States but is available in India (BioVac-A) and other countries (MEDVAC-A) including Guatemala, the Philippines, Bangladesh, Nepal, Uzbekistan, and Chile. Live attenuated hepatitis A vaccine is well-tolerated and highly immunogenic [<a href="#rid20">20-24</a>]. Live attenuated virus has been observed in the stools of individuals who received the vaccine (75 percent), although HAV transmission from vaccinees to unvaccinated seronegative individuals has not been observed.</p><p class="headingAnchor" id="H1674300173"><span class="h4">Efficacy</span><span class="headingEndMark"> — </span>Vaccination is superior to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> with respect to achievable antibody concentrations and durability of immune response [<a href="#rid13">13,14</a>]. The seroconversion rate (defined as an antibody concentration of &gt;20 milli-international units/mL measured by enzyme-linked immunosorbent assay) following primary vaccination series approximates 100 percent in healthy adults and children [<a href="#rid25">25-30</a>]. Since <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> became available in the United States in 1995, the rate of HAV infection has declined by 95 percent  (<a class="graphic graphic_figure graphicRef60763" href="/d/graphic/60763.html" rel="external">figure 2</a>) [<a href="#rid31">31,32</a>].</p><p>The single-antigen inactivated <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccines</a>, HAVRIX and VAQTA, have comparable immunogenicity; fewer side effects (most commonly local reactions) were observed with VAQTA [<a href="#rid33">33</a>]. The combination inactivated <a class="drug drug_general" data-topicid="8953" href="/d/drug information/8953.html" rel="external">hepatitis A-hepatitis B vaccine</a>, TWINRIX, is also well tolerated and highly immunogenic [<a href="#rid34">34,35</a>].</p><p>In healthy individuals, the persistence of antibody in adults is &gt;95 percent more than 20 years after vaccination [<a href="#rid36">36-38</a>] and in children is &gt;85 percent more than 15 to 20 years after vaccination [<a href="#rid39">39,40</a>].</p><p>In infants as young as age 2 months, hepatitis vaccine has been demonstrated to be safe and efficacious; however, vaccination of infants &lt;12 months may be associated with potential interference with passively acquired maternal antibody [<a href="#rid30">30,41,42</a>]. For these reasons, administration of a travel-related dose to infants age 6 to 11 months should not be counted toward the routine two-dose series [<a href="#rid3">3</a>].</p><p>In individuals with advanced liver disease, the serologic response to HAV vaccination may be diminished; if feasible, patients with liver disease should undergo vaccination before development of advanced disease. In one study comparing vaccination response among patients with decompensated disease to patients with compensated disease, seroconversion rates and serum antibody concentrations were lower among those with decompensated disease [<a href="#rid43">43</a>]; Child-Pugh class B or C was predictive of a lower response rate. (See  <a class="medical medical_review" href="/d/html/3891.html" rel="external">"Immunizations for adults with chronic liver disease"</a>.)</p><p>In immunocompromised individuals, the serologic response to HAV vaccination may be diminished. In HIV-infected individuals, seroconversion rates range from 52 percent to 94 percent [<a href="#rid44">44</a>]. Individuals with lower CD4 cell counts (&lt;300 cells/mm<sup>3</sup>) have lower seroconversion rates than those with CD4 cell counts ≥300 cells/mm<sup>3</sup> (87 percent versus 100 percent) [<a href="#rid45">45</a>]. Among patients with rheumatoid arthritis on tumor necrosis factor inhibitors and/or <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, a good response to the two-dose vaccination series was observed in one study (86 percent seroconversion), but one dose of vaccine was insufficient protection (33 percent seroconversion rate six months later) [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H1959443183"><span class="h4">Dosing and administration</span></p><p class="headingAnchor" id="H1984878628"><span class="h5">Clinical approach</span><span class="headingEndMark"> — </span>Immunization with single-antigen inactivated <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> (HAVRIX or VAQTA) consists of two doses for children and adults; dosing is summarized in the table  (<a class="graphic graphic_table graphicRef110077" href="/d/graphic/110077.html" rel="external">table 2</a>). Immunization with the combination inactivated <a class="drug drug_general" data-topicid="8953" href="/d/drug information/8953.html" rel="external">hepatitis A-hepatitis B vaccine</a>, TWINRIX, consists of three doses for adults; it is not indicated for children. (See  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p>For healthy individuals ≤40 years, the first dose of single-antigen <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> should be given as soon as travel to areas with an intermediate or high rate of hepatitis A infection is considered and can be given at any time prior to departure.</p><p>For individuals &gt;40 years, immunocompromised individuals, and persons with chronic liver disease or other chronic medical conditions with insufficient time to receive the full two-dose vaccination series before traveling, the first dose of vaccine should be administered together with a dose of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> at a separate injection site. (See <a class="local">'Passive immunization'</a> below.)</p><p>There is no need for HAV booster vaccination after completion of the primary two-dose vaccination series.</p><p>If the immunization schedule is interrupted, the second dose can be given without restarting the series. It is good practice to use the same brand of vaccine to complete a course. If this is not possible, products for the second dose are interchangeable (eg, VAQTA can be used for the second dose following primary dose of HAVRIX and vice versa).</p><p>The most common adverse events are fever, injection-site reaction, rash, and headache. Serious adverse events (including Guillain-Barré syndrome, elevated liver biochemical tests, and immune thrombocytopenia) have been reported [<a href="#rid22">22,47,48</a>], although their relationship to vaccination is uncertain.</p><p>The inactivated HAV vaccine can be given concurrently with the vaccines for diphtheria, tetanus, pneumococcus, typhoid, cholera, Japanese encephalitis, rabies, or yellow fever without adversely affecting immunogenicity or safety [<a href="#rid15">15,49,50</a>]. Injections should be given at different sites. Studies in children ≤18 suggest that the HAV vaccine does not affect immunogenicity or reactogenicity to diphtheria-tetanus-acellular pertussis, <em>Haemophilus influenzae</em> type b, hepatitis B, measles-mumps-rubella, pneumococcus, oral poliovirus, or inactivated poliovirus vaccines [<a href="#rid15">15,50-53</a>].</p><p>Data on the safety of hepatitis A vaccination during pregnancy are limited; because the vaccine is produced from inactivated HAV, the theoretical risk to the developing fetus is low. The risk associated with vaccination should be weighed against the risk for hepatitis A exposure [<a href="#rid12">12</a>]. Hepatitis A vaccination is warranted for pregnant women who have a specific risk (such as international travel)  (<a class="graphic graphic_figure graphicRef62130" href="/d/graphic/62130.html" rel="external">figure 3</a>).</p><p class="headingAnchor" id="H4059726233"><span class="h5">Limited role for single-dose strategy</span><span class="headingEndMark"> — </span>In October 2022, the World Health Organization issued guidance indicating that, for children ≥12 months, inactivated <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> may be administered as either a single-dose (off-label) or two-dose schedule [<a href="#rid54">54</a>]. This approach may be useful during hepatitis A outbreaks, emphasizing early intervention focused on a self-contained or well-defined population. This guidance is based in part on a 2012 systematic review including 13 studies and more than 800 children in which protective anti-HAV antibody levels persisted for up to 14 years following administration of single vaccine dose [<a href="#rid55">55</a>].</p><p>The WHO guidance continues to favor a two-dose schedule for adults ≥40 years, due to a lack of evidence for a single-dose strategy (with respect to immunogenicity or long-term protection) in this group.</p><p class="headingAnchor" id="H688804511"><span class="h3">Passive immunization</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">Immune globulin</a> can decrease the incidence of HAV infection by more than 90 percent [<a href="#rid56">56-59</a>]. Pre-exposure protection against HAV via passive immunization with immune globulin is warranted for nonimmune individuals at risk for hepatitis A exposure in the following categories  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) [<a href="#rid3">3,60</a>]:</p><p>Groups warranting <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> in <strong>addition</strong> to HAV vaccination (administered at a separate anatomic site) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Adult travelers &gt;40 years, based on the provider's risk assessment.</p><p></p><p class="bulletIndent1">Travelers &gt;40 years who may warrant <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> in addition to HAV vaccination include individuals at risk for relatively severe manifestations of hepatitis A infection, individuals with diminished ability to mount an adequate immune response to HAV vaccine, and individuals with increased risk for HAV transmission following exposure (eg, high endemicity of HAV in the area of travel).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Individuals with chronic liver disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompromised individuals incapable of mounting an adequate immune response to HAV vaccine.</p><p></p><p>Groups warranting <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> (in the absence of HAV vaccination) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Infant travelers &lt;6 months of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Travelers for whom vaccine is contraindicated (eg, who are allergic to the <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a>).</p><p></p><p>The <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> product available in the United States is GamaSTAN. Dosing consists of 0.1 mL/kg intramuscularly (for anticipated risk of exposure up to one month) or 0.2 mL/kg intramuscularly (for anticipated risk of exposure up to two months); for anticipated risk of exposure greater than two months, a repeat dose of 0.2 mL/kg should be administered every two months for the duration of exposure risk [<a href="#rid61">61,62</a>]. </p><p>This dosing regimen was increased from the prior dosing regimen in July 2017 due to concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma [<a href="#rid63">63</a>].</p><p>Widespread use of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> for hepatitis A prophylaxis is precluded by expense, injection site discomfort, need for repeat administration, and risk of bloodborne pathogen transmission (since the preparation is derived from pooled blood products). (See  <a class="medical medical_review" href="/d/html/3890.html" rel="external">"Immunizations for travel"</a>.)</p><p class="headingAnchor" id="H2092950"><span class="h1">PROTECTION FOLLOWING EXPOSURE</span></p><p class="headingAnchor" id="H3929206487"><span class="h2">Indications</span><span class="headingEndMark"> — </span>Individuals who warrant postexposure protection (ie, <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> and/or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>) after exposure to HAV include  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) [<a href="#rid12">12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Close personal contacts of an individual with laboratory-confirmed HAV infection:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Household and sexual contacts</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Individuals who have shared illicit drugs</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Childcare center contacts, in the setting of ≥1 case of hepatitis A among children or staff or ≥2 household cases of center attendees:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For centers providing care to children in diapers – Postexposure protection is warranted for all previously unvaccinated staff and attendees. In the setting of an outbreak (cases in ≥3 families), postexposure protection is also appropriate for household members of diaper-wearing children.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For centers providing care to children who no longer wear diapers – Postexposure protection is warranted for classroom contacts of the index patient (but not for children or staff in other classrooms).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Food handlers:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In establishments with a food handler diagnosed with hepatitis A, postexposure protection is warranted for other food handlers at the same establishment. Administration of postexposure protection to patrons is typically not indicated; it is appropriate if the food handler had diarrhea or poor hygienic practices and directly handled uncooked foods or foods following cooking, and patrons can be identified and prophylaxed within two weeks of exposure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Postexposure prophylaxis is reasonable in settings in which repeated exposures to hepatitis A might have occurred, such as institutional cafeterias.</p><p></p><p>Postexposure prophylaxis is not warranted in association with a single case of hepatitis A in a school, office, or hospital if the source of infection is outside the school or work setting. Rather, careful hygienic practices should be emphasized (see <a class="local">'Hygienic practices'</a> below). However, if it is determined that hepatitis A has spread among students in a school or among patients and health care workers in a hospital, postexposure protection is warranted for unvaccinated individuals who have had close contact with an infected person.</p><p class="headingAnchor" id="H650026901"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>The approach to HAV postexposure prophylaxis is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with recent HAV exposure who have not previously received HAV vaccine, postexposure prophylaxis should be administered with either a single dose of single-antigen HAV vaccine or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> as soon as possible, within two weeks of exposure  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) [<a href="#rid3">3,5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For healthy individuals aged ≥12 months, HAV vaccine should be administered. Vaccination is preferred over <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> since it induces active immunity and greater durability of protection, is easier to administer, and is more readily available than immune globulin.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals &gt;40 years, HAV vaccine should be administered; in addition, <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> may be administered (depending on individual risk assessment), because of limited data regarding vaccine performance in this age group and because of the more severe manifestations of hepatitis A in older adults [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals ≥12 months who are immunocompromised or have chronic liver disease, both HAV vaccine and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> should be administered in different anatomic sites.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children &lt;12 months and for individuals for whom HAV vaccine is contraindicated (eg, who are allergic to the vaccine), <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> should be administered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals with HIV infection and recent high-risk HAV exposure, administration of postexposure prophylaxis may be warranted regardless of prior vaccination history or immune status [<a href="#rid65">65</a>].</p><p></p><p>The <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> product available in the United States is GamaSTAN. Dosing for postexposure prophylaxis consists of 0.1 mL/kg intramuscularly. This dosing regimen was increased from the prior dosing in September 2017 due to decreasing prevalence of previous HAV infection among plasma donors in the United States [<a href="#rid61">61,63</a>].</p><p>For long-term immunity, the HAV vaccination should be completed with a second dose at least six months after the first dose; however, the second dose is not necessary for postexposure prophylaxis.</p><p>The above approach is based on a study including 1090 healthy individuals (ages 2 to 40) who were contacts of HAV cases and susceptible to HAV infection [<a href="#rid66">66</a>]. Subjects were randomly assigned to HAV vaccine or <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> within 14 days after exposure. The primary outcome (laboratory-confirmed symptomatic HAV) occurred in a similar proportion of patients in the vaccine and immune globulin groups (4.4 versus 3.3 percent), suggesting that the interventions provide comparable protection.</p><p>The combination <a class="drug drug_general" data-topicid="8953" href="/d/drug information/8953.html" rel="external">hepatitis A-hepatitis B vaccine</a>, TWINRIX, should not be used for postexposure prophylaxis.</p><p class="headingAnchor" id="H3756837891"><span class="h1">HYGIENIC PRACTICES</span><span class="headingEndMark"> — </span>Hygienic practices for prevention of HAV infection include [<a href="#rid67">67,68</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Handwashing (including after using the bathroom, changing diapers, and before preparing or eating foods).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding tap water and raw foods in areas with poor sanitation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Heating foods appropriately (the virus can be inactivated by heating to &gt;185°F [&gt;85°C] for one minute). Cooked foods can transmit HAV if the temperature during food preparation is inadequate to kill the virus or if food is contaminated after cooking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chlorine, iodine, and disinfecting solutions (household bleach 1:100 dilution) are effective for inactivation of HAV.</p><p></p><p class="headingAnchor" id="H264049597"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109228.html" rel="external">"Society guideline links: Immunizations in children and adolescents"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115404.html" rel="external">"Society guideline links: Travel medicine"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/16201.html" rel="external">"Patient education: Hepatitis A (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4572.html" rel="external">"Patient education: Hepatitis A (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H7718719"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Hepatitis A (HAV) infection is usually self-limited, and treatment consists of supportive care. Medications that might cause liver damage or are metabolized by the liver should be used with caution. Full clinical and biochemical recovery are observed within two to three months in most patients, and complete recovery is observed by six months in nearly all patients. HAV infection confers lifelong immunity. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protection prior to exposure</strong> – Prior to hepatitis A exposure, the primary tool for protection is vaccination, which is superior to <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> with respect to achievable antibody concentrations and durability of immune response. Individuals who warrant protection prior to potential hepatitis A exposure include  (<a class="graphic graphic_table graphicRef119479" href="/d/graphic/119479.html" rel="external">table 1</a>) (see <a class="local">'Indications'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All children aged 12 to 23 months.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>All children and adolescents aged 2 to 18 years who have not previously received <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> (ie, children and adolescents are recommended for catch-up vaccination). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For infants age 6 to 11 months who are traveling internationally, vaccination should be administered; the travel-related dose should not be counted toward the routine two-dose series [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals at increased risk for HAV infection:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals traveling to or working in countries with high or intermediate rates of HAV; some experts advise that travelers outside the United States consider hepatitis A vaccination regardless of their destination [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Men who have sex with men.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals who use injection or noninjection illegal drugs.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals with occupational risk for exposure, including individuals working with HAV-infected primates or with HAV in a research laboratory.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals who anticipate close personal contact with an international adoptee.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals experiencing homelessness.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Unvaccinated individuals in outbreak settings who are at risk for HAV infection or at risk for severe disease from HAV.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals in settings that provide services in which a high proportion of adults are at increased risk for HAV infection (eg, settings with a focus on those who use injection or noninjection illegal drugs, group homes, and nonresidential day care facilities for developmentally disabled persons).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Individuals at increased risk for severe disease from HAV infection:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals with chronic liver disease, including but not limited to individuals with hepatitis B virus infection, hepatitis C virus infection, cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, or an alanine aminotransferase or aspartate aminotransferase level persistently greater than twice the upper limit of normal. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Individuals ≥1 year with HIV infection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other individuals recommended for vaccination:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Pregnant women at risk for HAV infection or severe disease from HAV infection based on risk categories summarized above. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Any person who requests vaccination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine dosing and administration</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunization with single-antigen inactivated <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> (HAVRIX or VAQTA) consists of two doses for children and adults; dosing is summarized in the table  (<a class="graphic graphic_table graphicRef110077" href="/d/graphic/110077.html" rel="external">table 2</a>). Immunization with the combination inactivated <a class="drug drug_general" data-topicid="8953" href="/d/drug information/8953.html" rel="external">hepatitis A-hepatitis B vaccine</a>, TWINRIX, consists of three doses for adults; it is not indicated for children. (See <a class="local">'Dosing and administration'</a> above and  <a class="medical medical_review" href="/d/html/3641.html" rel="external">"Hepatitis B virus immunization in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For healthy individuals ≤40 years, the first dose of single-antigen <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> should be given as soon as travel to areas with risk of hepatitis A infection is considered and can be given at any time prior to departure. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For individuals &gt;40 years, immunocompromised individuals, and persons with chronic liver disease or other chronic medical conditions with insufficient time to receive the full two-dose vaccination series before traveling, the first dose of vaccine should be administered together with a dose of <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> at a separate injection site. (See <a class="local">'Dosing and administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other groups who warrant pre-exposure protection against HAV via passive immunization with <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a> include individuals who are allergic to the <a class="drug drug_general" data-topicid="8519" href="/d/drug information/8519.html" rel="external">hepatitis A vaccine</a> and children &lt;12 months of age. (See <a class="local">'Passive immunization'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protection following exposure</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indications</strong> – Individuals who may warrant postexposure protection after exposure to HAV include (see <a class="local">'Indications'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Close personal contacts of an individual with laboratory-confirmed HAV infection</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Child care center contacts, in the setting of ≥1 case of hepatitis A among children or staff or ≥2 household cases of center attendees</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Food handlers</p><p></p><p class="bulletIndent2">Postexposure prophylaxis is not warranted in association with a single case of hepatitis A in a school, office, or hospital. Rather, careful hygienic practices should be emphasized. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical approach</strong> – Tools for protection against HAV following exposure include vaccination and <a class="drug drug_general" data-topicid="16471" href="/d/drug information/16471.html" rel="external">immune globulin</a>; the approach depends on individual patient circumstances. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hygienic practices</strong> – Hygienic practices for prevention of HAV infection include handwashing, avoiding tap water and raw foods in areas with poor sanitation, and heating foods appropriately (the virus can be inactivated by heating to &gt;185°F [&gt;85°C] for one minute). Cooked foods can transmit HAV if the temperature during food preparation is inadequate to kill the virus or if food is contaminated after cooking. (See <a class="local">'Hygienic practices'</a> above.)</p><p></p><p class="headingAnchor" id="H32682131"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Catherine Cheney, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Koff RS. Clinical manifestations and diagnosis of hepatitis A virus infection. Vaccine 1992; 10 Suppl 1:S15.</a></li><li><a class="nounderline abstract_t">Nelson NP, Weng MK, Hofmeister MG, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep 2020; 69:1.</a></li><li><a class="nounderline abstract_t">Nelson NP, Link-Gelles R, Hofmeister MG, et al. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel. MMWR Morb Mortal Wkly Rep 2018; 67:1216.</a></li><li><a class="nounderline abstract_t">Foster M, Ramachandran S, Myatt K, et al. Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017. MMWR Morb Mortal Wkly Rep 2018; 67:1208.</a></li><li><a class="nounderline abstract_t">Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2007; 56:1080.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC), Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep 2009; 58:1006.</a></li><li><a class="nounderline abstract_t">American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for administering hepatitis A vaccine to contacts of international adoptees. Pediatrics 2011; 128:803.</a></li><li><a class="nounderline abstract_t">Doshani M, Weng M, Moore KL, et al. Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness. MMWR Morb Mortal Wkly Rep 2019; 68:153.</a></li><li><a class="nounderline abstract_t">Freedman M, Kroger A, Hunter P, et al. Recommended Adult Immunization Schedule, United States, 2020. Ann Intern Med 2020; 172:337.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Health Information for International Travel 2020: The Yellow Book. https://wwwnc.cdc.gov/travel/page/yellowbook-home (Accessed on October 29, 2020).</li><li class="breakAll">World Health Organization. Hepatitis A. http://www.who.int/mediacentre/factsheets/fs328/en/ (Accessed on February 17, 2017).</li><li class="breakAll">Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. http://www.cdc.gov/hepatitis/hav/havfaq.htm#vaccine (Accessed on October 05, 2016).</li><li><a class="nounderline abstract_t">Leentvaar-Kuijpers A, Coutinho RA, Brulein V, Safary A. Simultaneous passive and active immunization against hepatitis A. Vaccine 1992; 10 Suppl 1:S138.</a></li><li><a class="nounderline abstract_t">Shouval D, Ashur Y, Adler R, et al. Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin. J Hepatol 1993; 18 Suppl 2:S32.</a></li><li><a class="nounderline abstract_t">Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.</a></li><li><a class="nounderline abstract_t">Bryan JP, Nelson M. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines. Arch Intern Med 1994; 154:663.</a></li><li><a class="nounderline abstract_t">Bell BP, Kruszon-Moran D, Shapiro CN, et al. Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine 2005; 23:5798.</a></li><li><a class="nounderline abstract_t">Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1.</a></li><li><a class="nounderline abstract_t">Armstrong ME, Giesa PA, Davide JP, et al. Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 1993; 18 Suppl 2:S20.</a></li><li><a class="nounderline abstract_t">Mao JS, Xie RY, Huang HY, et al. Studies in monkeys of attenuated hepatitis A variants. Sci Sin B 1988; 31:338.</a></li><li><a class="nounderline abstract_t">Mao JS, Dong DX, Zhang HY, et al. Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989; 159:621.</a></li><li><a class="nounderline abstract_t">Midthun K, Ellerbeck E, Gershman K, et al. Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 1991; 163:735.</a></li><li><a class="nounderline abstract_t">Mao JS. Development of live, attenuated hepatitis A vaccine (H2-strain). Vaccine 1990; 8:523.</a></li><li><a class="nounderline abstract_t">Wang XY, Xu ZY, Ma JC, et al. Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up. Vaccine 2007; 25:446.</a></li><li><a class="nounderline abstract_t">Provost PJ, Hilleman MR. An inactivated hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med 1978; 159:201.</a></li><li><a class="nounderline abstract_t">André FE, D'Hondt E, Delem A, Safary A. Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings. Vaccine 1992; 10 Suppl 1:S160.</a></li><li><a class="nounderline abstract_t">Just M, Berger R. Reactogenicity and immunogenicity of inactivated hepatitis A vaccines. Vaccine 1992; 10 Suppl 1:S110.</a></li><li><a class="nounderline abstract_t">McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995; 171:676.</a></li><li><a class="nounderline abstract_t">Balcarek KB, Bagley MR, Pass RF, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995; 171 Suppl 1:S70.</a></li><li><a class="nounderline abstract_t">Bell BP, Negus S, Fiore AE, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J 2007; 26:116.</a></li><li><a class="nounderline abstract_t">Ly KN, Klevens RM. Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults. J Infect Dis 2015; 212:176.</a></li><li><a class="nounderline abstract_t">Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005; 294:194.</a></li><li><a class="nounderline abstract_t">Braconier JH, Wennerholm S, Norrby SR. Comparative immunogenicity and tolerance of Vaqta and Havrix. Vaccine 1999; 17:2181.</a></li><li><a class="nounderline abstract_t">Ambrosch F, Wiedermann G, André FE, et al. Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 1994; 44:452.</a></li><li class="breakAll">Van Damme P, Thoelen S, Cramm M, et al. Reactogenicity and immunogenicity of a combined hepatitis A and hepatitis B vaccine in healthy adults. In: Viral Hepatitis and Liver Disease, Nishioka K, Suzuki H, Mishiro S, Oda T (Eds), Springer, Tokyo, Japan 1994. p.514.</li><li><a class="nounderline abstract_t">Bovier PA, Bock J, Ebengo TF, et al. Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine. J Med Virol 2010; 82:1629.</a></li><li><a class="nounderline abstract_t">Hens N, Habteab Ghebretinsae A, Hardt K, et al. Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults. Vaccine 2014; 32:1507.</a></li><li><a class="nounderline abstract_t">Theeten H, Van Herck K, Van Der Meeren O, et al. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015; 33:5723.</a></li><li><a class="nounderline abstract_t">López EL, Contrini MM, Mistchenko A, et al. Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children. Pediatr Infect Dis J 2015; 34:417.</a></li><li><a class="nounderline abstract_t">Raczniak GA, Bulkow LR, Bruce MG, et al. Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis 2013; 207:493.</a></li><li><a class="nounderline abstract_t">Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000; 19:1045.</a></li><li><a class="nounderline abstract_t">Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004; 144:327.</a></li><li><a class="nounderline abstract_t">Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001; 34:28.</a></li><li><a class="nounderline abstract_t">Overton ET, Nurutdinova D, Sungkanuparph S, et al. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat 2007; 14:189.</a></li><li><a class="nounderline abstract_t">Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004; 39:1207.</a></li><li><a class="nounderline abstract_t">Askling HH, Rombo L, van Vollenhoven R, et al. Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study. Travel Med Infect Dis 2014; 12:134.</a></li><li><a class="nounderline abstract_t">Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327:453.</a></li><li class="breakAll">HAVRIX IM injection, hepatitis A vaccine IM injection. GlaxoSmithKline, Research Triangle Park, NC 2011.</li><li class="breakAll">Kruppenbacher J, Biensie U, Bock HL, Clemens R. Coadministration of an inactivated hepatitis A vaccine with other travelers vaccines: Interference with the immune response. Proc 34th Intersci Conf on Antimicrobial Agents and Chemotherapy, American Society of Microbiologists, Washington, 1994; 256.</li><li><a class="nounderline abstract_t">Trofa AF, Levin M, Marchant CD, et al. Immunogenicity and safety of an inactivated hepatitis a vaccine administered concomitantly with a pneumococcal conjugate vaccine in healthy children 15 months of age. Pediatr Infect Dis J 2008; 27:658.</a></li><li><a class="nounderline abstract_t">Nolan T, Bernstein H, Blatter MM, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics 2006; 118:e602.</a></li><li><a class="nounderline abstract_t">Guerra FA, Gress J, Werzberger A, et al. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J 2006; 25:912.</a></li><li><a class="nounderline abstract_t">Dagan R, Amir J, Livni G, et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr Infect Dis J 2007; 26:787.</a></li><li class="breakAll">World Health Organization. Weekly Epidemiological Record, 2022, vol. 97 (‎40)‎, 493 - 512. https://apps.who.int/iris/handle/10665/363396 (Accessed on November 29, 2022).</li><li><a class="nounderline abstract_t">Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines. A systematic review. Vaccine 2012; 31:3.</a></li><li><a class="nounderline abstract_t">Stokes J, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin: Preliminary note. JAMA 1945; 127:144.</a></li><li><a class="nounderline abstract_t">Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992; 14:580.</a></li><li><a class="nounderline abstract_t">Conrad ME, Lemon SM. Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin. J Infect Dis 1987; 156:56.</a></li><li><a class="nounderline abstract_t">Stapleton JT. Passive immunization against hepatitis A. Vaccine 1992; 10 Suppl 1:S45.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. https://www.cdc.gov/hepatitis/hav/havfaq.htm#D1 (Accessed on September 08, 2017).</li><li class="breakAll">US Food and Drug Administration. New Recommendations to Increase the Dose of GamaSTAN S/D (Immune Globulin [Human]) When Used for Prophylaxis for Hepatitis A. https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm574795.htm (Accessed on September 07, 2017).</li><li><a class="nounderline abstract_t">Nelson NP. Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis. MMWR Morb Mortal Wkly Rep 2017; 66:959.</a></li><li><a class="nounderline abstract_t">Tejada-Strop A, Costafreda MI, Dimitrova Z, et al. Evaluation of Potencies of Immune Globulin Products Against Hepatitis A. JAMA Intern Med 2017; 177:430.</a></li><li><a class="nounderline abstract_t">Link-Gelles R, Hofmeister MG, Nelson NP. Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use. Vaccine 2018; 36:2745.</a></li><li><a class="nounderline abstract_t">Brennan J, Moore K, Sizemore L, et al. Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018. MMWR Morb Mortal Wkly Rep 2019; 68:328.</a></li><li><a class="nounderline abstract_t">Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357:1685.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Hepatitis A Questions and Answers for Health Professionals. http://www.cdc.gov/hepatitis/hav/havfaq.htm#general (Accessed on July 13, 2016).</li><li><a class="nounderline abstract_t">Mbithi JN, Springthorpe VS, Boulet JR, Sattar SA. Survival of hepatitis A virus on human hands and its transfer on contact with animate and inanimate surfaces. J Clin Microbiol 1992; 30:757.</a></li></ol></div><div id="topicVersionRevision">Topic 3900 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335649" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical manifestations and diagnosis of hepatitis A virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32614811" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383742" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383739" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hepatitis A Virus Outbreaks Associated with Drug Use and Homelessness - California, Kentucky, Michigan, and Utah, 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947967" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19763077" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21949136" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Recommendations for administering hepatitis A vaccine to contacts of international adoptees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763295" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Persons Experiencing Homelessness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016359" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recommended Adult Immunization Schedule, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016359" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Recommended Adult Immunization Schedule, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016359" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recommended Adult Immunization Schedule, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016359" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Recommended Adult Immunization Schedule, United States, 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335646" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Simultaneous passive and active immunization against hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182270" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Safety, tolerability, and immunogenicity of an inactivated hepatitis A vaccine: effects of single and booster injections, and comparison to administration of immune globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16708058" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8129500" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16307834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10543657" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8182268" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2842861" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Studies in monkeys of attenuated hepatitis A variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2538518" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849160" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1965075" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Development of live, attenuated hepatitis A vaccine (H2-strain).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949710" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: results from 8-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/213786" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : An inactivated hepatitis A virus vaccine prepared from infected marmoset liver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335652" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: rationale and summary of findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1362031" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Reactogenicity and immunogenicity of inactivated hepatitis A vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876615" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7876652" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17259872" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immunogenicity of an inactivated hepatitis A vaccine in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25637352" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Trends in disease and complications of hepatitis A virus infection in the United States, 1999-2011: a new concern for adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014593" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Incidence of hepatitis A in the United States in the era of vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10367952" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Comparative immunogenicity and tolerance of Vaqta and Havrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897380" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897380" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20827757" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Predicted 30-year protection after vaccination with an aluminum-free virosomal hepatitis A vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24508042" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26190091" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25764099" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Modeling the long-term persistence of hepatitis A antibody after a two-dose vaccination schedule in Argentinean children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23204169" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long-term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11099084" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15001936" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11431730" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305885" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Predictors of immunity after hepatitis A vaccination in HIV-infected persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15486846" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24529746" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320740" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320740" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1320740" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18536623" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Immunogenicity and safety of an inactivated hepatitis a vaccine administered concomitantly with a pneumococcal conjugate vaccine in healthy children 15 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16950952" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17006287" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721372" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17721372" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22609026" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Long-term protective effects of hepatitis A vaccines. A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The prevention and attenuation of infectious hepatitis by gamma globulin: Preliminary note</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554845" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Immunoglobulin prophylaxis for hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3110307" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevention of endemic icteric viral hepatitis by administration of immune serum gamma globulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335658" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Passive immunization against hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335658" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Passive immunization against hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1335658" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Passive immunization against hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28910270" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28097299" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Evaluation of Potencies of Immune Globulin Products Against Hepatitis A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29673941" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Use of hepatitis A vaccine for post-exposure prophylaxis in individuals over 40 years of age: A systematic review of published studies and recommendations for vaccine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30973852" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Notes from the Field: Acute Hepatitis A Virus Infection Among Previously Vaccinated Persons with HIV Infection - Tennessee, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947390" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Hepatitis A vaccine versus immune globulin for postexposure prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17947390" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hepatitis A vaccine versus immune globulin for postexposure prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1315331" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Survival of hepatitis A virus on human hands and its transfer on contact with animate and inanimate surfaces.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
